Three years survival outcome and continued cemiplimab (CEMI) beyond progression with the addition of chemotherapy (chemo) for patients (pts) with advanced non-small cell lung cancer (NSCLC): The EMPOWER-lung 1 trial

Basit Öğe Kaydı
dc.authorid0000-0002-7071-2471
dc.contributor.authorHo, G. F.
dc.contributor.authorOzguroglu, M.
dc.contributor.authorKılıçkap, S.
dc.contributor.authorSezer, A.
dc.contributor.authorGümüş, M.
dc.contributor.authorBondarenko, I.
dc.contributor.authorGogishvili, M.
dc.date.accessioned2025-05-10T19:48:32Z
dc.date.issued2022
dc.departmentİstanbul Medeniyet Üniversitesi
dc.descriptionESMO Asia Congress -- DEC 02-04, 2022 -- Singapore, SINGAPORE
dc.description.abstract[No abstract available]
dc.description.sponsorshipEuropean Soc Med Oncol
dc.description.sponsorshipRegeneron Pharmaceuticals, Inc.; Sanofi
dc.description.sponsorshipRegeneron Pharmaceuticals, Inc., and Sanofi.
dc.identifier.doi10.1016/j.annonc.2022.10.366
dc.identifier.endpageS1571
dc.identifier.issn0923-7534
dc.identifier.issn1569-8041
dc.identifier.scopusqualityQ1
dc.identifier.startpageS1570
dc.identifier.urihttps://doi.org/10.1016/j.annonc.2022.10.366
dc.identifier.urihttps://hdl.handle.net/20.500.14730/11744
dc.identifier.volume33
dc.identifier.wosWOS:000897943700333
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.language.isoen
dc.publisherElsevier
dc.relation.ispartofAnnals of Oncology
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WOS_20250302
dc.titleThree years survival outcome and continued cemiplimab (CEMI) beyond progression with the addition of chemotherapy (chemo) for patients (pts) with advanced non-small cell lung cancer (NSCLC): The EMPOWER-lung 1 trial
dc.typeConference Object

Dosyalar

Orijinal paket

Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
11744.pdf
Boyut:
150.61 KB
Biçim:
Adobe Portable Document Format
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu